We hereby congratulate the Scientific Founder, Prof. Erkki Ruoslahti, and the entire team at Cend on a successful merge and going public (NASDAQ: LSTA)!
BICI is privileged to have partnered with the research team and wish the company continued success as a public company. We celebrate this milestone alongside all incredible partners and board members. We are grateful for their contributions.
Lisata Therapeutics now has approximately $76 million in cash and investments following the close of the merger, and is trading on Nasdaq under the ticker symbol LSTA. Learn more in Lisata’s press release.